Loading...
Loading...
Stifel Nicolaus initiated coverage on St. Jude Medical
STJ with a Hold rating.
Stifel Nicolaus said, "We are initiating coverage of St. Jude Medical Inc.
(STJ) with a Hold rating on the shares. With top-line growth slowing and
lingering uncertainties about the impact of the Riata/Durata ICD lead
controversy resolution, a possible FDA Warning Letter, and no visible significant near-term positive catalyst, we are inclined to remain on the sidelines, pending greater visibility on these issues."
St. Jude Medical closed at $35.03 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in